Navigation Links
iBio Passes Commercial Technology Transfer Milestone
Date:4/22/2013

NEWARK, Del., April 22, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced the achievement of a critical technology transfer milestone verified by an independent third party laboratory. The validation milestone comprised proof that an independent party, without guidance or assistance from iBio, could use the iBioLaunch™ system to reliably replicate production of commercial yields of targeted biopharmaceuticals including vaccines and therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

"In light of our recently announced commercial collaborations, this is an important demonstration that our technology can be readily utilized by others for commercialization of their respective products," said Robert Erwin , iBio's President. "To prove that, we designed the milestone to require the third party laboratory to implement the iBioLaunch system without assistance from iBio."

On February 19, iBio announced the grant of a license for the use of its iBioLaunch platform for development and production of a licensee's proprietary therapeutic product. On April 9, iBio announced another licensee's commitment for development of a multiproduct commercial facility based upon the iBioLaunch platform.

Although it is now proven that the iBioLaunch system could be employed by third parties even without support or guidance from iBio, iBio's actual business commitments to its licensees include assisting them to efficiently implement standard operating procedures for the use of iBio's proprietary technology, and provision of quality assurance and quality control documentation and procedures for product and site-specific implementation. When required, iBio also provides staff training in collaboration with the Fraunhofer USA Center for Molecular Biotechnology, which operates a state-of-the-art cGMP pilot facility in Delaware based on the iBioLaunch platform.  

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform.  The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.  The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect.  The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contacts

Robert Erwin ,
President
302-355-2335
rerwin@ibioinc.com   

  


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. John Velyvis MD Surpasses 550 Robotic Assisted Partial Knee Resurfacing Procedures
2. Mobile MIM for Diagnostic Imaging Surpasses 250,000 Downloads
3. European Market for Dental Instruments Surpasses $652 Million, According to New Market Research
4. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
5. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
6. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
7. New Autism Detection System Commercialized through Partnership of IP Shakti, LLC and Shizuoka University
8. Minimally Invasive Devices Raises $9 Million in Series B Financing to Commercialize Laparoscopic Visualization Product
9. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
10. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
11. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... The West Virginia Medical Institute (WVMI) ... The name change aligns the entire company with its existing Quality Insights branded ... “We are very proud of the achievements associated with the West Virginia Medical ...
(Date:12/8/2016)... ... 2016 , ... Russ DiGilio , founder and owner ... campaign which supported local breast cancer organizations during National Breast Cancer Awareness Month ... initiative, and we’re very pleased with the participation in every franchisee’s community,” ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):